Salute e Benessere

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment…

The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer's disease The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare coverage of LEQEMBITOKYO and CAMBRIDGE, Mass., July06, 2023(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:...

Esophageal Cancer Market to Proliferate at a CAGR of 5.9% During the Study…

Key Takeaways from the Esophageal Cancer Market Report Key Takeaways from the Esophageal Cancer Market Report Discover which therapies are expected to grab the major esophageal cancer market share @Esophageal Cancer Market Report Esophageal Cancer Overview Esophageal cancer arises when cancer cells originate in the esophagus, a tube-like tissue that connects the throat and stomach. The esophagus transfers food from the mouth to the stomach. The cancer develops in the inner...

Groupe Casino: Equity offers now available online

Equity offers now available online Paris, 6 July 6 2023Further to the press release of 4 July 2023, Casino announces that it has today posted on its website the full text of the offers received from EP Global Commerce a.s. and Fimalac, as well as from 3F Holding :EP Global Commerce / Fimalac3F Holding ***This press release was prepared solely for information purposes and should not be construed as a solicitation or an offer to buy or sell securities or...

Bamboo Clothing Market to Reach $3 Billion, Globally, by 2032 at 9.1% CAGR…

Download Report Sample PDF: https://www.alliedmarketresearch.com/request-sample/75312 Download Report Sample PDF:https://www.alliedmarketresearch.com/request-sample/75312 Prime determinants of growth The growth of the global bamboo clothing market is driven by factors such as growth in awareness toward sustainable fashion brands among consumers, environmentally friendly materials, increase in purchasing power of consumers, and achieving economies of scale by manufacturers...

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 6convertible bonds in Oxurion resulting in a EUR 150 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US–...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM, Boston, MA, US – July 6 , 2023 – 7 .00PM CETOxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on July 6, 2023, from...

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of June 30 , 2023(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (July6 , 2023 - 6:00 pm)– As of June 30, 2023, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of...

Amniotic Products Market worth $1,289 million | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191575976 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191575976 Browse in-depth TOC on "Amniotic Products Market" 107 - Tables 32 - Figures 179 - Pages Amniotic Products Market Scope: UK in European amniotic products market to witness the highest shares during the forecast period. TheEuropeamniotic products market is...

Healthcare Claim Management Market Zooms Towards Billion-Dollar Valuation…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=17729 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=17729 Browse in-depth TOCon" Healthcare Claim Management Market " 202 - Pages 126 – Tables 37 – Figures Healthcare Claim Management Market: Rising Demand for Efficient Solutions to Optimize Revenue in the Healthcare Sector The global healthcare claim management market is witnessing substantial...

Primary Cells Market worth $2.8 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960 Browse in-depth TOC on "Primary Cells Market"179 - Tables37 - Figures222 - Pages Primary Cells Market Scope: "In 2022, human primary cells segment accounted for the dominant share of the primary cells market, by origin." On the basis of origin, the primary cells...

Metastatic Cancer Drugs Market to Reach $136.9 Billion, Globally, by 2032 at…

Download Sample Copy- https://www.alliedmarketresearch.com/request-sample/109835 Download Sample Copy-https://www.alliedmarketresearch.com/request-sample/109835 Prime determinants of growth Increase in prevalence of metastatic cancer cases worldwide, ongoing advancements in cancer detection and diagnosis, and increase in adoption of personalized medicine has revolutionized the field of healthcare, particularly in the treatment of metastatic cancer are the factors that drive the...

Tools Market to Reach $153.2 Billion, Globally, by 2032 at 5.2% CAGR: Allied…

Download Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/107608 Download Free Sample Report @https://www.alliedmarketresearch.com/request-sample/107608 Prime determinants of growth The tools market is primarily driven by various factors such as a rise in construction activities, a rise in small-scale industries involved in metal fabrication, a growth in demand for furniture and other wooden items, and a rise in DIY culture along with home renovation and...

Novavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the…

The Phase 3 PREVENT-19 trial demonstrated Nuvaxovid's reassuring safety profile as well as efficacy as a primary series in adults, the immunogenicity and safety as a booster dose in adults, and the efficacy and safety as a primary series in individuals aged 12 and older. The Phase 3 PREVENT-19 trial demonstrated Nuvaxovid's reassuring safety profile as well as efficacy as a primary series in adults, the immunogenicity and safety as a booster dose in adults, and the efficacy and safety as a...

Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and…

Collaboration expands Carrick's clinical-stage Oncology program This agreement covers the execution of a Phase 1b/2 clinical trial to evaluate the novel combination of Carrick's samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, and Arvinas' vepdegestrant (ARV-471), an investigational oral PROTAC ®(PROteolysis TArgeting Chimera) estrogen receptor protein degrader being developed in collaboration with Pfizer, in patients who have received prior CDK4/6i, with ER+, HER2-...

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the…

NEW YORK and LONDON, July06, 2023(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the European Medicines Agency (EMA) has issued a positive opinion on the company's application for orphan drug designation for nomacopan as a treatment in hematopoietic stem cell transplantation. The application included nomacopan clinical data from the treatment of...

Sectra publishes Annual Report and Sustainability Report for 2022/2023

A summary of the financial year is also available on the website. The 2022/2023 financial year in brief summarizes the value we create for various stakeholders, highlights from our operations, and a selection of financial performance measures. A summary of the financial year is also available on the website.The 2022/2023 financial year in briefsummarizes the value we create for various stakeholders, highlights from our operations, and a selection of financial performance measures. This...

Leading Innovators in Gene Therapy Market: 5 Biggest Stocks Companies in 2023

American Medical Association Releases Language of First New Current Procedural…

New code will facilitate reimbursement for psychedelic therapy in the US, if approved COMPASS Pathways to hold webinar on new code on Tuesday, July 11, 8:00 am EDT (1:00 pm BST) LONDON, July06, 2023(GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the American Medical Association hasreleased the languageof its new Current...

Dental Consumables Market to be Worth $57.7 Billion by 2030: Grand View…

Read full market research report, "Dental Consumables Market Size, Share & Trends Analysis Report By Product Type (Dental Implants, Crowns & Bridges, Dental Biomaterials, Orthodontic Materials), By End-use (Hospitals, Dental Clinics), By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research. Read full market research report, " Dental Consumables Market Size, Share & Trends Analysis Report By Product Type (Dental Implants, Crowns & Bridges…

Extracorporeal Membrane Oxygenation (ECMO) Machine Market to Reach $445.7…

Read 110-page market research report, "Extracorporeal Membrane Oxygenation Machine Market Size, Share, & Trends Analysis Report By Component, By Modality (VA, VV, AV) By Patient Type, By Application, By Region And Segment Forecasts, 2023 - 2030", published by Grand View Research. Read 110-page market research report, " Extracorporeal Membrane Oxygenation Machine Market Size, Share, & Trends Analysis Report By Component, By Modality (VA, VV, AV) By Patient Type, By…

Next Generation Sequencing Market to Reach $33.15 Billion by 2030: Grand View…

Read 300 page market research report, "Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology (Targeted Sequencing & Resequencing), By Product, By Application , By Workflow, By End-use, By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research. Read 300 page market research report, " Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology (Targeted Sequencing & Resequencing), By…

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase…

This study is being led by Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences. Professor Li Hanzhong, head of the Department of Surgery at Peking Union Medical College Hospital, is serving as the Principal Investigator, leading a team of top experts in the field of bladder cancer in China to carry out this study. Asieris plans to file a new drug application with the National Medical Products Administration (NMPA) in the future, pending clinical trial progress and…

Hansa Biopharma to host conference call to provide half year results for…

To participate in the telephone conference, please use the dial-in details provided below: To participate in the telephone conference, please use the dial-in details provided below: Sweden : +46 10 884 80 16 United Kingdom : +44 20 3936 2999 United States : +1 646 664 1960 Participant access code: 323180 The webcast will be available onhttps://events.q4inc.com/attendee/206699686 Financial calendar and events 2023 July 18, 2023 William Blair Conference...

Chr. Hansen Holding A/S Interim Report Q3 2022/23

July 6, 2023 – Company announcement no. 7Strong execution by the organization drives solid Q3 results Statement by CEO Mauricio Graber:“The solid results for Q3 prove the strength of the Chr. Hansen organization which continues to deliver first-class products and innovative solutions to customers around the world, while the process with Novozymes to complete the proposed merger is progressing. Organic growth came in at 9%, driven mainly by pricing initiatives. EBIT b.s.i. increased by...

Altri Comunicati